ReviewClinical and molecular hepatology2016
A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016.
Review in Clinical and molecular hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 5 syntheses or guidelines pooled it, 272 citations in OpenAlex.
- Robotic versus laparoscopic liver resection for liver malignancy: a systematic review and meta-analysis of propensity score-matched studies.Surgical endoscopy · 2024Pooled it
- Efficacy of fusion imaging for immediate post-ablation assessment of malignant liver neoplasms: A systematic review.Cancer medicine · 2023Pooled it
- Leveraging deep phenotyping from health check-up cohort with 10,000 Korean individuals for phenome-wide association study of 136 traits.Scientific reports · 2022Pooled it
- Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis.BMJ open · 2018Pooled it
- Comparison of laparoscopic liver resection for lesions located in anterolateral and posterosuperior segments: a meta-analysis.Surgical endoscopy · 2017Pooled it
- Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- A Computational Method for Systematic Comparison of Clinical Practice Guidelines.Clinical and public health guidelines · 2026Article
- The nVR model: prediction of LI-RADS treatment response nonviable recurrence of hepatocellular carcinoma after primary transarterial chemoembolization.Abdominal radiology (New York) · 2025Article
- Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer.Journal of liver transplantation · 2025Article
- Competing risk analysis of surgical resectionTranslational cancer research · 2025Article
- Effects of ER-phagy regulatory genes on the microenvironment of hepatocellular carcinoma: a comprehensive analysis.Discover oncology · 2025Article
- A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024.Journal of liver cancer · 2025Article
- Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma.Cancers · 2025Article
- Outcome and Prognosis of Invasive Treatment for Hepatocellular Carcinoma in Very Elderly Patients Over 90 Years Old.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Impact of pre-sarcopenia on outcomes of transarterial chemoembolization in unresectable hepatocellular carcinoma.Scientific reports · 2024Article
- HCV- and HBV-mediated liver cancer converge on similar transcriptomic landscapes and immune profiles.bioRxiv : the preprint server for biology · 2024Article
- A Retrospective Cohort Analysis of Transarterial Chemoembolization for Hepatocellular Cancer at a Tertiary Center in Switzerland.Journal of clinical medicine · 2024Article
- Synergistic Effects of Nanoscale CaOInternational journal of nanomedicine · 2024Article
- Progress in bioprinting technology for tissue regeneration.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2023Review
- Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies.Journal of cancer research and clinical oncology · 2023Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many guidelines for hepatocellular carcinoma (HCC) have been published and updated globally. In contrast to other cancers, there is a range of treatment options for HCC involving several multidisciplinary care of the patient. Consequently, enormous heterogeneity in management trends has been observed. To support standard care for HCC, we systematically appraised 8 current guidelines for HCC around the world, including 3 guidelines from Asia, 2 from Europe, and 3 from the United States according to the selection criteria of credibility influence and multi-faceted. After a systematic appraisal, we found that these guidelines have both similarities and dissimilarities in terms of surveillance and treatment allocation recommendations due to regional differences in disease and other variables (diagnosis, staging systems) secondary to the lack of a solid, high level of evidence. In contrast to other tumors, the geographic differences in tumor biology (i.e., areas of increased hepatitis B prevalence) and available resources (organ availability for transplantation, medical technology, accessibility to treatment, health systems, and health resources) make it impractical to have an internationally universal guideline for all patients with HCC. Although Barcelona-Clinic Liver Cancer (BCLC) has long been dominant system for treatment-guiding staging of HCC, many Asia-pacific experts do not fully agree with its principle. The concepts of BCLC, for surgical resection or other locoregional therapy, are considered too conservative. Asian guidelines represent consensus about surgical resection and TACE indication for more advanced tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.